News

Schering-Plough has reported interim results from an ongoing phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor. Narlaprevir demonstrated potent antiviral activity in treatment-naive patients

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) reported that Benlysta (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal phase 3 trials in seropositive patients

PRA International opened a new office facility in Seoul, South Korea. To accommodate rapid growth and further broaden PRA’s ability to deliver clinical service excellence, the company has

Gilead Sciences (Gilead), in collaboration with GlaxoSmithKline (GSK) has announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a

Sosei Group (Sosei) has entered into a definitive distribution agreement with ASKA Pharmaceuticals (ASKA) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo). NorLevo is an oral

Usana Health Sciences (Usana) has launched seasonal Vitamin D supplement. The supplement will be available every year from November to March. The company claimed that its supplement has

Immunovaccine has entered into a master services agreement with Cato Research Canada (Cato), to assist the company in managing an upcoming Phase 1 clinical trial for DPX-0907, a

Boston Scientific has received CE mark for its Promus Element Everolimus-Eluting Coronary Stent System (PEEECSS), the company’s third-generation drug-eluting stent (DES) technology. Boston Scientific will begin marketing the

Caliper Life Sciences presented the benefits of the LabChipGX platform for high throughput screening and characterization assays for biological drugs at a training session for reviewers from the